DNLI Stock Analysis: Denali Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.109m USD | 12M Return: 12.5% | US24823R1059 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 38.5M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Denali Therapeutics Inc. (NASDAQ: DNLI) is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases. Headquartered in South San Francisco, California, and incorporated in 2013 (formerly SPR Pharma Inc., renamed in March 2015), the company operates within the biotechnology sub-industry of the healthcare sector, a field characterized by high R&D investment and pipeline-driven valuation.
The companys pipeline spans multiple modalities and disease targets, including small molecules such as Eclitasertib (a RIPK1 inhibitor for peripheral inflammatory diseases), BIIB122/DNL151 (an LRRK2 inhibitor for Parkinsons disease), and DNL126 (for MPS IIIA/Sanfilippo Syndrome A). It also develops enzyme replacement therapies like DNL310 (Tividenofusp alfa) for MPS II (Hunter Syndrome). A distinguishing element of Denalis business model is its proprietary blood-brain barrier crossing technology platforms-the Enzyme TransportVehicle (TV), Oligonucleotide TV (OTV), and antibody TV-which enable delivery of large therapeutics into the brain, addressing a key historical challenge in treating central nervous system disorders.
Additional TV-enabled programs target tau and alpha-synuclein for Alzheimers and Parkinsons diseases, respectively, along with DNL921 targeting Abeta for Alzheimers. The company maintains strategic collaborations with larger pharmaceutical partners such as Sanofi and Takeda, which support its development programs and provide validation of its platform approach.
- LRRK2 inhibitor Phase 3 Parkinsons trial results with Biogen partnership
- DNL310 Hunter Syndrome enzyme therapy FDA approval catalyst
- Rising R&D cash burn pressures capital raise timing
| Net Income: -511.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -2.28 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.37 > 3% & CFO -434.0m > Net Income -511.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (187.3m) vs 12m ago 9.25% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.31% > 50% (prev 0.0%; Δ 0.31% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.57 (Total Current Assets 753.9m - Total Current Liabilities 90.1m) / Total Assets 1.16b |
| B: -1.99 (Retained Earnings -2.31b / Total Assets 1.16b) |
| C: -0.44 (EBIT TTM -511.3m / Avg Total Assets 1.16b) |
| D: 2.59 (Book Value of Equity 835.2m / Total Liabilities 322.8m) |
| Altman-Z'' = -2.98 = D |
As of October 16, 2026, the stock is trading at USD 18.34 with a total of 1,565,967 shares traded. Over the past week, the price has changed by -1.77%, over one month by -10.01%, over three months by -20.33% and over the past year by +12.45%.
Current recommended Stop Loss: 17.30 (which is 5.7% or 1.2 ATR below the current price).
Denali Therapeutics has received a consensus analysts rating of 4.80. Therefore, it is recommended to buy DNLI.
- StrongBuy: 17
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35.8 | 94.9% |
P/S = 862.6616
P/B = 3.9159
Revenue TTM = 3.60m USD
EBIT TTM = -511.3m USD
EBITDA TTM = -498.2m USD
Long Term Debt = unknown (none)
Short Term Debt = 9.55m USD (from shortTermDebt, last fiscal year)
Debt = 59.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 32.2m
Net Debt = -650.8m USD (calculated: Debt 59.7m - CCE 710.5m)
Enterprise Value = 2.46b USD (3.11b + Debt 59.7m - CCE 710.5m)
Interest Coverage Ratio = unknown (Ebit TTM -511.3m / Interest Expense TTM 0.0)
EV/FCF = -6.00x (Enterprise Value 2.46b / FCF TTM -409.4m)
FCF Yield = -16.65% (FCF TTM -409.4m / Enterprise Value 2.46b)
FCF Margin = -11.4k% (FCF TTM -409.4m / Revenue TTM 3.60m)
Net Margin = -14.2k% (Net Income TTM -511.5m / Revenue TTM 3.60m)
Gross Margin = unknown ((Revenue TTM 3.60m - Cost of Revenue TTM 107.8m) / Revenue TTM)
Tobins Q-Ratio = 2.12 (Enterprise Value 2.46b / Total Assets 1.16b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 59.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -404.0m (EBIT -511.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.40 (Total Current Assets 753.9m / Total Current Liabilities 101.9m)
Debt / Equity = 0.07 (Debt 59.7m / totalStockholderEquity, last quarter 835.2m)
Debt / EBITDA = 1.31 (negative EBITDA) (Net Debt -650.8m / EBITDA -498.2m)
Debt / FCF = 1.59 (negative FCF - burning cash) (Net Debt -650.8m / FCF TTM -409.4m)
Total Stockholder Equity = 925.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.01% (Net Income -511.5m / Total Assets 1.16b)
RoE = -55.27% (Net Income TTM -511.5m / Total Stockholder Equity 925.3m)
RoCE = -47.88% (EBIT -511.3m / Capital Employed (Total Assets 1.16b - Current Liab 90.1m))
RoIC = -37.50% (negative operating profit) (NOPAT -404.0m / Invested Capital 1.08b)
WACC = 11.08% (E(3.11b)/V(3.17b) * Re(11.29%) + D(59.7m)/V(3.17b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.92 | Cagr: 10.57%
[DCF] Fair Price = unknown (Cash Flow -409.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.53 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.25 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.37 | Chg30d=+13.02% | Revisions=+40% | Analysts=17
EPS current Year (2026-12-31): EPS=-2.22 | Chg30d=+5.33% | Revisions=-25% | GrowthEPS=+25.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.42 | Chg30d=+0.58% | Revisions=-17% | GrowthEPS=-8.9% | GrowthRev=+156.1%
[Analyst] Revisions Ratio: +0% (up=3, down=3)